HS-10504

Phase 1Small molecule

Jiangsu Hansoh Pharmaceutical Co., Ltd.

HS-10504 is one of 54 small molecule programs targeting Hepatic Impairment. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hepatic ImpairmentNot yet recruiting

Locally Advanced or Metastatic NSCLCRecruiting

Phase IBNot yet recruiting

Hepatic ImpairmentPhase 1

Not yet recruiting

Locally Advanced or Metastatic NSCLCPhase 1

Recruiting

Phase IBPhase 1

Not yet recruiting

Competition

Competitive Landscape

22 competitors in Hepatic Impairment

#DrugCompanyPhaseTrials

Vanflyta

Daiichi Sankyo

Phase 1

1 2

Gomekli

SSpringWorks Therapeutics, Inc.

Phase 1

1 3

Beqalzi

BBeOne Medicines

Phase 1

1 4

Luye

Ascentage Pharma Group Inc.

Phase 1

1 5

DWP16001

Daewoong Pharmaceutical Co. LTD.

Phase 1

1 6

Lipaglyn

ZZydus Therapeutics Inc.

Phase 1

1 7

Casdatifan

Arcus Biosciences

Phase 1

1 8

ASTX727

Taiho Oncology, Inc.

Phase 1

1 9

Atirmociclib

Pfizer

Phase 1

1 10

PF-07328948

Pfizer

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Not yet recruiting

Study completion

NCT07770217

Q1 2027

Phase 1Recruiting

Locally Advanced or Metastatic NSCLC

NCT06461156

Phase 1Not yet recruiting

Study completion

NCT07764692

Q4 2027

Phase 1Not yet recruiting

Study completion

NCT07836504

Q4 2028

Phase 1Not yet recruiting

Phase IB

NCT07414953

Clinical

Trials by Indication[1]

Phase IB1 trial

A Phase Ib Study of HS-10504 Combined Therapy in NSCLC

Not yet recruiting· Jiangsu Hansoh Pharmaceutical Co., Ltd. logo

Jiangsu Hansoh Pharmaceutical Co., Ltd.·Phase 1·NCT07414953·400 enrolled

Advanced or Metastatic NSCLC1 trial

A Randomized, Controlled, Open-Label, Multicenter Phase III Study to Evaluate the Efficacy and Safety of HS-10504 Versus Platinum-Based Doublet Chemotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring EGFR C797S Mutation After Failure of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy

Recruiting· Jiangsu Hansoh Pharmaceutical Co., Ltd. logo

Jiangsu Hansoh Pharmaceutical Co., Ltd.·Phase 3·NCT07754123·206 enrolled

Locally Advanced or Metastatic NSCLC1 trial

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HS-10504 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC）

Recruiting· Jiangsu Hansoh Pharmaceutical Co., Ltd. logo

Jiangsu Hansoh Pharmaceutical Co., Ltd.·Phase 1·NCT06461156·230 enrolled

Unspecified3 trials

A Pharmacokinetic Study of HS-10504 in Participants With Hepatic Impairment and Normal Hepatic Function.

Not yet recruiting· Jiangsu Hansoh Pharmaceutical Co., Ltd. logo

Jiangsu Hansoh Pharmaceutical Co., Ltd.·Phase 1·NCT07836504·32 enrolled

A Phase I Clinical Trial to Evaluate the Effect of Rifampin on the Pharmacokinetics of HS-10504 in Healthy Participants

Not yet recruiting· Jiangsu Hansoh Pharmaceutical Co., Ltd. logo

Jiangsu Hansoh Pharmaceutical Co., Ltd.·Phase 1·NCT07770217·18 enrolled

A Phase I Clinical Trial to Evaluate the Effect of Itraconazole on the Pharmacokinetics of HS-10504 in Healthy Participants

Not yet recruiting· Jiangsu Hansoh Pharmaceutical Co., Ltd. logo

Jiangsu Hansoh Pharmaceutical Co., Ltd.·Phase 1·NCT07764692·8 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for HS-10504. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HS-10504 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HS-10504. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jiangsu Hansoh Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Jiangsu Hansoh Pharmaceutical Co., Ltd.

HS-10504

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q4 2027

Q4 2028

Trials by Indication[1]

Phase IB1 trial

Advanced or Metastatic NSCLC1 trial

Locally Advanced or Metastatic NSCLC1 trial

Unspecified3 trials

References

Drug Info

Quick Facts

Related News